Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole IV and Oral Suspension in Pediatric Neutropenia
NCT02452034Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of posaconazole in invasive fungal infection (IFI) (6 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve, Maximum Plasma Concentration and 5 more. Started Sep 2015; status: completed.
02
Drugs
posaconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT02452034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452034.